Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

[Society face to cancer: awareness and social actions].

Revue medicale suisse·2015
Same author

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Cancer treatment reviews·2012
Same author

What do prescribers think of biosimilars?

Targeted oncology·2012
Same author

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

European journal of cancer (Oxford, England : 1990)·2010

Related Experiment Video

Updated: Jul 7, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

[Medical oncology trends].

M S Aapro1

  • 1Institut multidisciplinaire d'oncologie, Clinique de Genolier, 1272 Genolier. maapro@genolier.net

Revue Medicale Suisse
|March 4, 2008
PubMed
Summary

Recent advances in medical oncology offer new hope for treating difficult cancers like hepatocarcinoma. While targeted therapies show promise, further research is needed to improve chemotherapy effectiveness and reduce patient toxicity.

Area of Science:

  • Medical Oncology
  • Hepatocellular Carcinoma Research
  • Cancer Therapeutics

Context:

  • The year 2007 marked a significant period for medical oncology, with new data impacting daily clinical practice across various cancer types.
  • Hepatocellular carcinoma (HCC), a historically difficult-to-treat malignancy, is now a focus of renewed research interest and therapeutic development.
  • Advances extend beyond targeted therapies to notable progress in chemotherapy, though specific areas require further investigation.

Purpose:

  • To review and highlight key published data from 2007 that have a major impact on daily medical oncology practice.
  • To specifically address recent advancements in the treatment of hepatocarcinoma, offering hope for patients with this challenging cancer.
  • To evaluate progress in both targeted cancer treatments and chemotherapy, identifying areas for future research focus.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Experiment Videos

Last Updated: Jul 7, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Summary:

  • Published data in 2007 have revitalized medical oncology, particularly for challenging tumors like hepatocarcinoma, offering new treatment avenues.
  • Significant progress has been observed in targeted cancer therapies, alongside remarkable developments in chemotherapy regimens.
  • The review acknowledges exceptions made for specific congress abstracts, underscoring their importance in advancing cancer care.

Impact:

  • Provides clinicians with critical updates on impactful data influencing daily practice in medical oncology.
  • Highlights emerging hope and therapeutic progress for hepatocarcinoma patients, a group with historically limited options.
  • Identifies a need for more focused research to enhance treatment response rates and survival outcomes while minimizing toxicity.